Synapto is an early-stage medical technology company transforming Alzheimer's Disease screening through portable EEG and Machine Learning.
Alzheimer's Disease is a devastating, irreversible, progressive brain disorder that slowly destroys memory, cognition, and eventually the ability to complete simple tasks. As the 6th leading cause of death in the United States, it is one of the most expensive diseases, costing close to $259 billion dollars annually in the US. Alzheimer’s disease biology can manifest in the brain up to 10 years prior to patient symptoms, however due to the cost-prohibitive and resource intensive nature of diagnosis, Alzheimer’s disease screening is not routine. Our innovative device moves away from costly neuroimaging diagnostic techniques and qualitative methods of diagnosis to a more robust, affordable, and accessible mode of analysis, a portable Electroencephalogram (EEG) + Artificial Intelligence system.
Our platform extracts complex mathematical characteristics from a patient’s brainwaves, and by engaging machine learning, decides whether that particular brainwave has signatures of neurodegeneration or is healthy.
A portable Electroencephalogram records highly sensitive electrical signals in the brain, which can then be inspected using novel methods of analyses. Recordings like these then allow machine learning models to predict the severity and progression of the disease. For research, Synapto is utilizing portable EEG from OpenBCI and other sources, making our platform unique in that it is more affordable and accessible than current EEG diagnostic measures.